Welcome to our dedicated page for Ardent Health SEC filings (Ticker: ARDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ardent Health, Inc. (NYSE: ARDT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Ardent Health is a healthcare company in the medical care facilities industry that operates 30 acute care hospitals and approximately 280 sites of care across six states, and its filings offer detailed information on its financial condition, capital structure, governance and material events.
Among the key documents available are Current Reports on Form 8-K, where Ardent Health reports significant developments. Recent 8-K filings describe quarterly financial results, including the release of earnings for specific quarters and the use of non-GAAP measures such as Adjusted EBITDA and Adjusted EBITDAR. These filings often incorporate the related earnings press release as an exhibit, providing definitions of non-GAAP metrics, reconciliations to GAAP measures and discussions of operating metrics like admissions, surgeries and net patient service revenue per adjusted admission.
Other 8-K filings detail financing and capital structure actions. For example, Ardent Health has reported amendments to its Amended and Restated Term Loan Credit Agreement and its Amended and Restated ABL Credit Agreement, extending term loan maturities, adjusting interest rate spreads over Term SOFR and the base rate, and updating baskets for certain negative covenants. Another 8-K describes the authorization of a stock repurchase program of up to $50.0 million of the company’s common stock, including the potential use of open market purchases, privately negotiated transactions, block trades and Rule 10b5-1 plans.
Filings also cover governance and executive matters, such as leadership changes and the treatment of departures under the company’s Executive Severance Plan. References to proxy statements and severance plan documents in these filings point investors to additional information on executive compensation and severance arrangements.
On Stock Titan, these ARDT filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain the substance of each filing, highlight key terms in credit agreements, clarify the implications of non-GAAP metrics and stock repurchase authorizations, and make it easier to understand how individual disclosures relate to Ardent Health’s hospital operations and financial profile.
Ardent Health, Inc. Chief Financial Officer Alfred Lumsdaine reported an equity compensation award on Common Stock. He acquired 61,081 shares on March 11, 2026 at a stated price of $0.00 per share, reflecting a grant or award rather than an open-market purchase.
According to the footnote, these shares were earned based on 2024 and 2025 performance under performance-vesting restricted stock units granted on July 18, 2024, and will vest on December 31, 2026 if he remains in service through that date. Following this award, he directly holds 272,228 Common Stock shares.
Chernin Ethan reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. President of Health Services Ethan Chernin reported receiving a grant of 32,408 shares of Common Stock as compensation, with no purchase price paid per share.
These shares were earned based on 2024 and 2025 performance under performance-vesting restricted stock units awarded on July 18, 2024. They will vest on December 31, 2026, contingent on continued service through that date. After this award, Chernin directly holds 68,396 shares of Ardent Health common stock.
Bonick Martin reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. President and CEO Martin Bonick received a grant of 195,316 shares of common stock at no cost as part of his equity compensation. These shares were earned based on 2024 and 2025 performance under performance-vesting restricted stock units awarded on July 18, 2024.
The granted shares will vest on December 31, 2026, contingent on his continued service through that date, meaning he does not fully own them until then. Following this award, Bonick directly holds 1,322,300 shares of Ardent Health common stock.
Byers David Raynor reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. reported that SVP & Chief Accounting Officer David Raynor Byers received a grant of 8,859 shares of common stock as a compensation award. These shares were earned based on 2024 and 2025 performance under performance-vesting restricted stock units and will vest on December 31, 2026, contingent on continued service through that date. Following this award, he directly holds 120,650 shares of common stock.
Ardent Health reported mixed fourth quarter and full-year 2025 results and issued 2026 guidance. Full-year 2025 revenue rose to $6.32 billion, up 6.0%, while Adjusted EBITDA increased 9.3% to $545 million, lifting the Adjusted EBITDA margin to 8.6%.
Fourth quarter revenue was $1.61 billion, essentially flat year over year, and Adjusted EBITDA fell 26.6% to $134 million as net income attributable to Ardent Health declined to $45 million, or $0.32 per diluted share. Management noted that prior-year results benefited from two quarters of New Mexico state directed payments.
Operations showed modest volume growth, with admissions up 1.5% and adjusted admissions up 2.0%, while net patient service revenue per adjusted admission decreased 2.4%. For 2025, net cash from operating activities climbed 49% to $471 million, ending the year with $710 million in cash and a net leverage ratio of 0.8x.
In 2025 the company repurchased 0.35 million shares for $3 million. For 2026, Ardent forecasts revenue of $6.4–$6.7 billion, net income attributable to Ardent Health of $129–$183 million, Adjusted EBITDA of $485–$535 million and diluted EPS of $0.90–$1.27, with adjusted admissions growth of 1.5–2.5% and capital expenditures of $225–$265 million.
Ardent Health, Inc. announced that its board of directors has authorized a stock repurchase program for up to $50.0 million of its common stock. The program has no specified expiration date, giving the company flexibility in timing any buybacks. Repurchases may be made through open market purchases, privately negotiated transactions, block trades or other transactions in line with applicable securities laws, including the pricing and volume requirements of Rule 10b-18 under the Exchange Act.
Ardent may also use Rule 10b5-1 plans to facilitate repurchases. The company is not obligated to repurchase any specific amount of shares and can modify, suspend or terminate the program at any time. It expects to fund any repurchases with existing cash and cash equivalents and ongoing cash from operations.
Ardent Health, Inc. reported Q3 2025 results with total revenue of $1,576,746,000 versus $1,449,817,000 a year ago. A change in accounting estimate reduced revenue by $42.6 million in the quarter after implementing a new revenue accounting system. Net (loss) income attributable to Ardent was $(23,478,000) (basic and diluted EPS $(0.17)), compared with net income of $26,322,000 (EPS $0.19) in Q3 2024.
For the first nine months, revenue reached $4,719,260,000 and net income attributable to Ardent was $90,855,000. Operating cash flow for the nine months was $247,075,000, ending cash was $609,441,000, and total assets were $5,154,373,000. The balance sheet showed long‑term debt (less current) of $1,087,023,000 and equity of $1,633,336,000.
Ardent refinanced its Term Loan B on September 18, 2025, cutting the margin by 50 bps (to Term SOFR + 2.25%) and extending maturity to September 2032. The company acquired 18 urgent care clinics on January 1, 2025 for $27.5 million. As of November 7, 2025, common shares outstanding were 143,187,681.
Ardent Health, Inc. (ARDT) furnished its third-quarter 2025 results press release. The company reported that, on November 12, 2025, it issued a press release covering financial results for the quarter ended September 30, 2025, and made it available as Exhibit 99.1 to a current report on Form 8-K under Item 2.02.
The information provided under Item 2.02, including Exhibit 99.1, is furnished rather than filed, meaning it is not subject to Section 18 of the Exchange Act and will only be incorporated by reference into other filings if expressly stated. The filing also lists Exhibit 104 for the cover page interactive data file. This is a routine disclosure that makes the company’s quarterly results press release part of the public record without triggering the liabilities associated with filed materials.
Ardent Health, Inc. (ARDT) Form 4: Chief Financial Officer Alfred Lumsdaine reported a transaction on 09/25/2025 in which 3,389 shares of the issuer's common stock were disposed of at a price of $13.19 per share. The filing states the shares were withheld to pay taxes upon vesting of restricted stock units. After the reported disposition, the reporting person beneficially owns 211,147 shares, held directly. The form was signed by an attorney-in-fact on 09/30/2025.
Stephen C. Petrovich, Executive Vice President, General Counsel and Assistant Secretary of Ardent Health, Inc. (ARDT), reported a routine share disposition on 09/25/2025. The filing shows 788 shares were withheld to satisfy tax withholding upon vesting of restricted stock units at a closing price of $13.19, and after that transaction Mr. Petrovich directly beneficially owned 718,303 shares. In addition, the filing discloses two family trusts each holding 186,225 shares, which the reporting person disclaims beneficial ownership of except for any pecuniary interest. The form is a standard Section 16 report documenting an internal tax-related share settlement rather than an open-market sale.